Dopamine agonist monotherapy in Parkinson's disease (Q28217350)

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

Europe PubMed Central

title

Dopamine agonist monotherapy in Parkinson's disease (English)

0 references

1 reference

0 references

C E Clarke

1

0 references

M Guttman

series ordinal

2

0 references

language of work or name

English

0 references

publication date

30 November 2002

0 references

published in

The Lancet

0 references

volume

360

0 references

issue

9347

0 references

page(s)

1767-9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Is it time to abandon functional imaging in the study of neuroprotection?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

Evaluating drug treatments for Parkinson's disease: how good are the trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021

When should levodopa be started?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911668-0

7 January 2021